Toggle Main Menu Toggle Search

ePrints

Novel targeting of cyclooxygenase-2 (COX-2) pre-mRNA using antisense morpholino oligonucleotides directed to the 3′ acceptor and 5′ donor splice sites of exon 4: Suppression of COX-2 activity in human amnion-derived WISH and myometrial cells

Lookup NU author(s): Dr Alison Tyson-Capper, Professor Nick Europe-Finner

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Increased expression of cyclooxygenase-2 (COX-2) has been implicated in the onset of both term and preterm labor. In this context, both selective and nonselective COX-2 inhibitors have been used in clinical trials to determine their efficacy in delaying preterm labor. However, recent evidence indicates that these tocolytics may have potentially adverse fetal and maternal side effects. Therefore, the development of more specific and nontoxic agents to inhibit COX-2 needs to be considered. We have evaluated whether antisense morpholino oligonucleotides have therapeutic potential in inhibiting COX-2 by specifically targeting both the 3′ and 5′ acceptor and donor sites of exon 4 of COX-2's pre-mRNA sequence. Confocal microscopy on "live" cells illustrated high levels of penetrance of antisense morpholino oligonucleotides using the Endo-Porter formula (Gene-Tools, LLC, Philomath, OR), with delivery efficiencies of 82 and 78%, respectively, in amnion-derived WISH and myometrial cells. Substantial inhibition by the morpholino oligonucleotides of COX-2 expression, induced by lipopolysaccharide administration, was observed at both the mRNA and protein levels. Loss of enzymic activity of COX-2 was confirmed using a sensitive COX enzyme activity assay, which reflects the rate of conversion of arachidonic acid to prostaglandin H2. Our results indicate that antisense morpholino oligonucleotides significantly inhibit expression and activity of this enzyme in in vitro cultures of amnion-WISH and myometrial cells. The potential thus exists that a similar approach can be mimicked in vivo to produce a highly specific and nontoxic strategy to inhibit COX-2 activity with its subsequent effects on the better management of preterm labor and other inflammatory conditions. Copyright © 2006 The American Society for Pharmacology and Experimental Therapeutics.


Publication metadata

Author(s): Tyson-Capper AJ, Europe-Finner GN

Publication type: Article

Publication status: Published

Journal: Molecular Pharmacology

Year: 2006

Volume: 69

Issue: 3

Pages: 796-804

ISSN (print): 0026-895X

ISSN (electronic): 1521-0111

Publisher: American Society for Pharmacology and Experimental Therapeutics

URL: http://dx.doi.org/10.1124/mol.105.020529

DOI: 10.1124/mol.105.020529

PubMed id: 16354766


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share